VitaPancreaticCancer

The VitaPancreaticCancer formulation targets advanced pancreatic cancer through a highly synergistic mechanism involving cannabinoids, terpenes, and flavonoids, all encapsulated within a nanoemulsion system for enhanced bioavailability and precision targeting of cancer cells.

​

THC (Δ9-Tetrahydrocannabinol) exerts its anticancer effects primarily by binding to CB1 and CB2 receptors of the endocannabinoid system. Activation of these receptors triggers a cascade of intracellular signals, including the ceramide pathway, which promotes apoptosis in cancer cells. THC also inhibits cancer cell proliferation by inducing ER stress and the upregulation of p8 mRNA, a protein involved in stress responses leading to apoptosis.

​

THCV (Tetrahydrocannabivarin) acts as a CB1 receptor antagonist at low concentrations and a partial agonist at higher doses, modulating the PI3K/Akt and MAPK pathways involved in cell survival and proliferation. Its ability to inhibit CB1 receptor activity plays a role in reducing cancer cell growth and controlling tumor metabolism.

​

CBD (Cannabidiol) exhibits strong anti-inflammatory and anti-tumor properties. It inhibits ROS production and reduces NF-κB activation, which diminishes the pro-inflammatory environment that fosters tumor progression. CBD also blocks GPR55, a receptor linked to cancer cell migration, and modulates the expression of TRPV1 receptors, which further induces apoptosis in cancer cells.

​

CBG (Cannabigerol) is a CB1 and CB2 receptor partial agonist and shows anti-tumor activity by inhibiting ERK1/2 phosphorylation, leading to reduced cancer cell proliferation. It also influences PPARγ expression, a key transcription factor that regulates lipid metabolism and induces cancer cell differentiation and apoptosis.

​

CBC’s (Cannabichromene) anti-cancer properties stem from its ability to modulate the endocannabinoid system without directly binding to CB1 or CB2 receptors. Instead, it increases levels of anandamide, an endogenous cannabinoid, through inhibition of FAAH (Fatty Acid Amide Hydrolase), enhancing anti-inflammatory and apoptotic responses. CBC also displays anti-proliferative effects by suppressing the MAPK/ERK pathway.

​

Limonene, a monoterpene, exhibits anticancer properties through the modulation of Ras signaling pathways, which are often mutated in pancreatic cancer. By inhibiting protein prenylation, limonene disrupts the anchoring of Ras proteins to the cell membrane, thereby reducing cell proliferation and inducing apoptosis. Limonene also has antioxidant properties, reducing oxidative stress and protecting normal cells from free radical damage.

​

Kaempferol is a potent antioxidant and anti-inflammatory agent that modulates PI3K/Akt and NF-κB signaling pathways, key players in cancer cell survival and inflammation. It also inhibits VEGF expression, reducing tumor angiogenesis, and induces cell cycle arrest in the G2/M phase, halting the proliferation of cancer cells. Kaempferol's ability to modulate apoptotic pathways through the upregulation of Bax and the downregulation of Bcl-2 further enhances its role in tumor suppression.

​

The nanoemulsion formulation enhances the bioavailability of these hydrophobic compounds by encapsulating them in nano-sized droplets (less than 200 nm). This allows for efficient absorption through the digestive system and better cellular uptake. The smaller particle size improves tissue penetration, particularly into pancreatic tumors, which are known for their dense stromal architecture. The nanoemulsion ensures a controlled release of cannabinoids, terpenes, and flavonoids, maintaining sustained therapeutic levels in the bloodstream and within tumor microenvironments.

​

The entourage effect of cannabinoids, terpenes, and flavonoids amplifies the therapeutic efficacy of each component. For instance, cannabinoids like CBD reduce the psychoactive effects of THC while enhancing its anticancer properties, and limonene improves the absorption and synergistic interaction of cannabinoids. Together, these compounds modulate multiple molecular pathways such as PI3K/Akt, MAPK, NF-κB, and VEGF, ultimately leading to tumor cell apoptosis, inhibition of metastasis, and reduction of angiogenesis.

This multi-targeted approach not only makes VitaPancreaticCancer highly effective but also reduces side effects, enhancing patient safety by minimizing the required dosages of each component​.